Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175207
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Crespo Guardo, Alberto | - |
dc.contributor.author | Gómez, Carmen Elena | - |
dc.contributor.author | Díaz Brito, Vicens | - |
dc.contributor.author | Pich, Judit | - |
dc.contributor.author | Arnaiz Gargallo, Juan Alberto | - |
dc.contributor.author | Perdiguero, Beatriz | - |
dc.contributor.author | García Arriaza, Juan | - |
dc.contributor.author | GonzÁlez, Núria | - |
dc.contributor.author | Sorzano, Carlos O. S. | - |
dc.contributor.author | Jiménez, Laura | - |
dc.contributor.author | Jiménez, José Luis | - |
dc.contributor.author | Muñoz Fernández, María Ángeles | - |
dc.contributor.author | Gatell, José M. | - |
dc.contributor.author | Alcamí, José | - |
dc.contributor.author | Esteban, Mariano | - |
dc.contributor.author | López Bernaldo de Quirós, Juan Carlos | - |
dc.contributor.author | García Alcaide, Felipe | - |
dc.contributor.author | Plana Prades, Montserrat | - |
dc.contributor.author | RISVAC02boost study | - |
dc.date.accessioned | 2021-03-17T12:06:46Z | - |
dc.date.available | 2021-03-17T12:06:46Z | - |
dc.date.issued | 2017-10-24 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175207 | - |
dc.description.abstract | Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0186602 | - |
dc.relation.ispartof | PLoS One, 2017, vol. 12, num. 10, p. e0186602 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0186602 | - |
dc.rights | cc-by (c) Crespo Guardo, Alberto et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Vacunes antivíriques | - |
dc.subject.classification | Cèl·lules T | - |
dc.subject.other | HIV (Viruses) | - |
dc.subject.other | Viral vaccines | - |
dc.subject.other | T cells | - |
dc.title | Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 693519 | - |
dc.date.updated | 2021-03-17T12:06:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29065142 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
693519.pdf | 3.21 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License